Vaccination with Novabacs, the fourth new corona vaccine in Japan, has begun at medical institutions in Tokyo.

A vaccine developed by the American pharmaceutical company Nuvaxovid was approved last month and added to public vaccination on the 25th of this month.

On the 27th, inoculation began at Juntendo Clinic attached to Juntendo University School of Medicine in Bunkyo-ku, Tokyo, as part of an investigation to analyze side reactions and efficacy.

The Novabax vaccine works differently from Pfizer and Moderna, and is expected to be given to people who have had an allergic reaction to the previous vaccine or who have hit AstraZeneca up to the second time.

The five people who were vaccinated on the 27th also had the AstraZeneca vaccine so far, and a 62-year-old man who is an office worker said, "I was expecting it as a domestically produced vaccine, so I'm glad I got it." Was there.

At this medical institution, 500 people will be inoculated in the future, and changes in body temperature and inoculation site will be recorded for 4 weeks for analysis.

Kazuhisa Takahashi, director of Juntendo Clinic, said, "I would like to investigate thoroughly to give a sense of security to the vaccine."

Nuvaxovid vaccination has begun in local governments as well, with 5 million doses scheduled to be delivered to local governments by the end of July.